The Supreme Court paused a lower-court order that would have tightened in-person requirements for mifepristone, leaving the FDA’s 2023 distribution rules intact while litigation carries on and exposing sharp, public splits on the Court over state sovereignty, federal regulatory power, and how far constitutional limits extend on mailing abortion drugs.
The high court’s stay prevented a May 1 decision from the 5th Circuit from taking effect, so mail-order access and pharmacy dispensing of mifepristone remain permitted for now while the case goes back down to the appeals court. Drugmakers Danco and GenBioPro asked the Court to step in after the 5th Circuit had reinstated an in-person visit requirement. Two justices—Samuel Alito and Clarence Thomas—dissented in forceful terms, signaling the fight is far from over.
Justice Thomas anchored his opposition in a rarely invoked statute from 1873, arguing the Comstock Act could make mailing mifepristone a federal crime. He framed the emergency request by the manufacturers in stark language about criminal liability and harm to profiteers. That reasoning pushes the dispute beyond administrative law and into sweeping criminal exposure for mailing the drug.
“Applicants are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise. They cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes.”
Thomas has raised Comstock before during oral arguments in earlier mifepristone litigation, and his latest dissent makes clear he intends to keep pressing the point. The Court had unanimously avoided the substantive question in the 2024 case on standing grounds, a technical escape hatch that left the underlying legal conflict unresolved. With Thomas on record now, that unresolved substantive clash is more likely to land back before the bench.
Justice Alito wrote separately and used sharper rhetoric about the majority’s order, calling it “unreasoned” and warning that current practices may be undermining the Dobbs decision. Alito, who wrote Dobbs, sees the regulatory path used here as a direct challenge to state-enacted abortion restrictions. His dissent reads as an explicit signal to lower courts and future litigants about his view of federal overreach.
“The Court’s unreasoned order granting stays in this case is remarkable. What is at stake is the perpetration of a scheme to undermine our decision” overturning constitutional abortion rights.
The underlying lawsuit comes from Louisiana, which sued the FDA over its 2023 rule expanding telehealth prescriptions, pharmacy dispensing, and mail delivery of mifepristone. The state argued the rule undercut its near-total abortion ban, violated state sovereignty, and lacked adequate safety data to justify broad access. Those claims frame the dispute as one about federal administrative reach into core state policy choices.
Louisiana Attorney General Liz Murrill responded sharply after the order, calling the stay-blocking decision shocking and framing the distribution as unethical. She also faulted the Justice Department for not defending the state’s position against pharmaceutical makers. Her language underscores how this fight is as much political and moral as it is legal.
“It’s shocking that the Supreme Court would block this common-sense return to medically ethical practices and oversight.”
“DOJ did not defend Big Pharma, which is profiting from the illegal and unethical distribution of abortion pills. We will keep fighting.”
The Justice Department told the appeals court the challenge “would disrupt FDA’s ongoing review, and usurp FDA’s scientific role, but would also threaten chaos.” The FDA is actively reviewing safety protocols for mifepristone, and that administrative process could change the legal landscape depending on its findings. If the agency tightens requirements, some state concerns might be addressed without litigation; if not, states like Louisiana will press their case aggressively.
Drugmakers framed the stay as preserving the status quo. GenBioPro stressed continued access and commitment to evidence-based medicine, while Danco pointed to decades of safety data and millions of patient experiences supporting the drug’s record. Those statements were meant to reassure customers and regulators as the case winds back through the courts.
“With today’s Supreme Court decision, Americans’ access to mifepristone remains unchanged for now. GenBioPro is continuing to serve its customers and is committed to providing our evidence-based, essential medication to all who need it.”
“Over the years, FDA has reviewed extensive safety and effectiveness data from dozens of clinical trials and decades’ worth of real-world experience in millions of patients.”
The Court’s order is procedural: it leaves the 2023 FDA rule in place while the 5th Circuit reconsiders, and it offers no majority opinion explaining why. But the paired dissents are substantive roadmaps. Thomas’s Comstock theory would criminalize mailing the drug if it gained traction, while Alito’s framing invites challenges that present the FDA rule as a potential end-run around Dobbs. Those signals will shape how the appellate judges and future litigants approach the case.
The larger story is about competing claims of federal authority and state sovereignty, and how the Court manages high-voltage cultural conflicts without a single, cohesive voice. For now the status quo continues, but the dissents make clear that a final legal answer is still pending and could reshape access, enforcement, and the role of federal regulation in matters that states treat as fundamental policy choices.
